Sandoz & Henlius Deal
Sandoz, a global leader in generic and biosimilar medicines, announced that it has signed a global collaboration agreement with Shanghai Henlius Biotech Inc. (Henlius, ) to market a biosimilar of leading oncology therapy, ipilimumab (Yervoy).
The agreement is milestone-based for a total consideration of up to USD 301 million, including an upfront payment of USD 31 million and will target net reference-medicine sales of USD 2.5 billion. Under the terms of the agreement, Sandoz has exclusive commercial rights for a biosimilar of ipilimumab, HLX 13 in Australia, Canada, Europe, Japan and the US. The core sequence patent for ipilimumab expired in March 2025 in the US and will expire no later than February 2026 in the EU.
Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater. This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.